1	Household transmission of SARS-CoV-2 from adult index cases living v	vith
2	and without HIV in South Africa, 2020-2021: a case-ascertained, prospe	ective
3	observational household transmission study	

4	
5	Jackie Kleynhans, MPH (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
6	Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the
7	Witwatersrand, Johannesburg, South Africa.)
8	Sibongile Walaza, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
9	Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the
10	Witwatersrand, Johannesburg, South Africa.)
11	Neil A. Martinson, MD (Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa. Johns Hopkins
12	University Center for TB Research, Baltimore, Maryland, United States of America.)
13	Mzimasi Neti, MPH (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
14	Laboratory Service, Johannesburg, South Africa.)
15	Prof Anne von Gottberg, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National
16	Health Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the
17	Witwatersrand, Johannesburg, South Africa.)
18	Jinal N. Bhiman, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
19	Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand,
20	Johannesburg, South Africa.)
21	Dylan Toi, MD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
22	Laboratory Service, Johannesburg, South Africa.)
23	Daniel G. Amoako, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
24	Laboratory Service, Johannesburg, South Africa. School of Health Sciences, College of Health Sciences, University of KwaZulu-
25	Natal, KwaZulu-Natal, South Africa.)
26	Amelia Buys, ND (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
27	Laboratory Service, Johannesburg, South Africa.)
28	Kedibone Ndlangisa, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health
29	Laboratory Service, Johannesburg, South Africa.)

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

1 Nicole Wolter, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health 2 Laboratory Service, Johannesburg, South Africa. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, 3 Johannesburg, South Africa.) 4 Leisha Genade, MPH (Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.) 5 Lucia Maloma, BA(Hons) (Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.) 6 Juanita Chewparsad, MSc (Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.) 7 Limakatso Lebina, PhD (Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa. Africa Health 8 Research Institute (AHRI), Durban, South Africa) 9 Linda de Gouveia, ND (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health 10 Laboratory Service, Johannesburg, South Africa.) 11 Retshidisitswe Kotane, BCMP (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National 12 Health Laboratory Service, Johannesburg, South Africa.) 13 Stefano Tempia, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health 14 Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the 15 Witwatersrand, Johannesburg, South Africa.) 16 Prof Cheryl Cohen, PhD (Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health 17 Laboratory Service, Johannesburg, South Africa. School of Public Health, Faculty of Health Sciences, University of the 18 Witwatersrand, Johannesburg, South Africa.) 19 Corresponding author: Jackie Kleynhans. Address: Centre for Respiratory Diseases and Meningitis, National 20

21 Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

22 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

23 Email: jackiel@nicd.ac.za.

24 Running title: Household transmission of SARS-CoV-2

1 Abstract

2 Background

- 3 In South Africa, 19% of the adult population are living with HIV (LWH). Few data on the influence of
- 4 HIV on SARS-CoV-2 household transmission are available.

5 Methods

- 6 We performed a case-ascertained, prospective household transmission study of symptomatic index SARS-
- 7 CoV-2 cases LWH and HIV-uninfected adults and their contacts in South Africa, October 2020 to
- 8 September 2021. Households were followed up thrice weekly for 6 weeks to collect nasal swabs for
- 9 SARS-CoV-2 testing. We estimated household cumulative infection risk (HCIR) and duration of SARS-
- 10 CoV-2 positivity (at cycle threshold value <30 as proxy for high viral load).

11 Results

- 12 We recruited 131 index cases and 457 household contacts. HCIR was 59% (220/373); not differing by
- 13 index HIV status (60% [51/85] in cases LWH vs 58% [163/279] in HIV-uninfected cases, OR 1.0, 95% CI
- 14 0.4-2.3). HCIR increased with index case age (35-59 years: aOR 3.4 95% CI 1.5-7.8 and \geq 60 years: aOR
- 15 3.1, 95% CI 1.0-10.1) compared to 18-34 years, and contacts' age, 13-17 years (aOR 7.1, 95% CI 1.5-33.9)
- and 18-34 years (aOR 4.4, 95% CI 1.0-18.4) compared to <5 years. Mean positivity duration at high viral
- 17 load was 7 days (range 2-17), with longer positivity in cases LWH (aHR 0.4, 95%CI 0.1-0.9).
- 18 Conclusions
- 19 Index HIV status was not associated with higher HCIR, but cases LWH had longer positivity duration at
- high viral load. Adults aged >35 years were more likely to transmit, individuals aged 13-34 to acquire
- 21 SARS-CoV-2 in the household. As HIV infection may increase transmission, health services must
- 22 maintain HIV testing and antiretroviral therapy initiation.
- 23 Keywords: SARS-CoV-2, COVID-19, HIV, transmission, acquisition

2 Introduction

3 By January 2022, South Africa reported 3.6 million coronavirus disease 2019 (COVID-19) cases and 94.3 thousand deaths; the highest reported from Africa.[1, 2] South Africa experienced four severe acute 4 5 respiratory syndrome coronavirus 2 (SARS-CoV-2) waves: the first dominated by ancestral variants, 6 followed by Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529) variant waves, respectively.[3] Although incident HIV infections and AIDS-related deaths from 2010 to 2019 in South Africa reduced by 7 8 53% and 61%, respectively, the burden of HIV is still high, with an estimated 19% of the adult population 9 aged 15-49 living with HIV (LWH); the fourth highest in Sub-Saharan Africa.[4] The SARS-CoV-2 10 pandemic impacted several health programs, including HIV testing and care. During initial lockdowns there was a decline in HIV testing and antiretroviral therapy (ART) initiations, which gradually returned 11 to pre-lockdown levels after the lockdown in South Africa[5] and other Sub-Saharan African countries.[6] 12 Few studies report the influence of HIV infection on SARS-CoV-2, with most data available from high 13 income countries and little evidence from sub-Saharan Africa where most people LWH reside.[4] People 14 LWH are at greater risk for hospitalisation[7-10] and death[9-13] when infected with SARS-CoV-2, but 15 16 SARS-CoV-2 prevalence is similar between people LWH and HIV-uninfected individuals.[14] Risk for hospitalisation and death increases with decline in CD4+ T cells.[8, 9, 13] Limited data are available on 17 the role of HIV in transmission of SARS-CoV-2. One study showed no increase in household 18 19 transmission from, or acquisition of SARS-CoV-2 infection in people LWH.[2] People LWH with severe COVID-19 who are not virally suppressed shed SARS-CoV-2 for longer periods, [2, 15] which could lead 20 21 to increased secondary transmission.

We assessed household cumulative infection risk (HCIR), duration of SARS-CoV-2 positivity (episode
duration), serial interval in households with SARS-CoV-2 index cases LWH and HIV-uninfected during
October 2020 to September 2021 during Beta and Delta waves.

1 Methods

2 We conducted a case-ascertained, prospective observational household transmission study of household 3 contacts of symptomatic adult index SARS-CoV-2 cases LWH and HIV-uninfected at two sites in South 4 Africa, Klerksdorp (North West Province) and Soweto (Gauteng Province). Planned sample size was 264 and 176 contacts from households with an HIV-uninfected and HIV-infected index case, respectively 5 (detailed in supplement). Actual sample size was 344 and 103 household members exposed to an HIV-6 7 uninfected and HIV-infected index case, respectively. 8 Screening for index cases 9 Screening procedures are detailed in supplementary methods. In short, nasopharyngeal swabs were collected from clinic attendees aged ≥ 18 years with symptom onset ≤ 5 days prior to screening and tested 10 for SARS-CoV-2 using real-time reverse transcription polymerase chain reaction (rRT-PCR). 11 Household enrolment 12 13 We approached households of individuals who tested positive for SARS-CoV-2, with symptom onset less than 7 days prior, no household members reporting symptoms in 14 days prior to index screening. 14 Households with ≥ 3 eligible members (sharing ≥ 2 meals in same residence for ≥ 2 days/week), of whom 15

16 \geq 70% consented to participate were enrolled. Households that withdrew within 10 days from index

17 symptom start date were excluded from the analysis.

18 Index and household follow-up

We visited households thrice weekly for 6 weeks to collect nasal swabs, symptoms and healthcare seeking
behaviour from consenting household members. At the first and last study visits, clotted blood was

collected for serological testing. Follow-up started on 12 October 2020 and continued to 11 August 2021

and 28 September 2021 in Klerksdorp and Soweto, respectively.

23 SARS-CoV-2 detection

- 1 Nasopharyngeal (screening) and nasal (follow-up) specimens were tested for SARS-CoV-2 genes by
- 2 qualitative rRT-PCR, using the Allplex[™] 2019-nCoV kit (Seegene Inc., Seoul, South Korea). Specimens
- 3 were considered positive for SARS-CoV-2 if the cycle threshold (C_t) value was <40 for any gene target.

4 SARS-CoV-2 variants

- 5 We characterized the first SARS-CoV-2 positive specimen for each participant on the Allplex[™] SARS-
- 6 CoV-2 Variants I and II PCR assays (Seegene Inc., Seoul, Korea) and through full genome sequencing on
- 7 the Ion Torrent Genexus platform (Thermo Fisher Scientific, USA). We classified the infection episodes
- 8 as Alpha, Beta, Delta, non-Alpha/Beta/Delta or unknown variant (detailed in supplement).

9 Serology

- 10 We used an in-house ELISA to detect antibodies against SARS-CoV-2 spike protein[18] and
- 11 nucleocapsid protein using Roche Elecsys anti-SARS-CoV-2 assay. Individuals were considered
- 12 seropositive if they tested positive on either.

13 Statistical analysis

Definitions used are in Table 1. To assess factors associated with HCIR we used logistic regression 14 15 accounting for within site and household clustering using a mixed effects hierarchical regression model. To assess factors associated with a time to event analysis (serial interval and episode duration), we used a 16 17 multilevel mixed effects survival model with Weibull accelerated failure time analysis. Hazard ratios <1 correspond to longer episode duration than reference group used. Since multiple members from the same 18 19 household could potentially be included in the serial interval analysis, we controlled for both site and 20 household level clustering in in the analysis. In the episode duration analysis, we controlled for only site 21 clustering (one index per household). In addition to using site to control for clustering, it was also included as a co-variate in models. Episode duration was assessed at any C_1 value (<40) and C_1 <30 (proxy 22 23 for high viral load based on virus culture studies [19]). We first assessed co-variates on univariate 24 analysis, including all with p<0.2 in the multivariable analysis. We performed backwards elimination and kept all variables with p<0.05 in the final model, except those included *a priori*. We included site, SARSCoV-2 variant and index immune suppression related to HIV status (defined as CD4+ T cell count <200
cells/ml) in the HCIR and episode duration models *a priori* irrespective of statistical significance in the
multivariable model Site was included *a priori* in the serial interval analysis. Due to low SARS-CoV-2
vaccination coverage in study participants (only one contact, Table 2), vaccination status was not included
in our analyses.

7 Sensitivity analysis

8 To assess the influence of loss to follow-up, we performed a sensitivity analysis including only

9 households where 65% of enrolled household members completed 65% of follow-up visits in the first

10 three weeks of follow-up. To explore the effect of previous SARS-CoV-2 infection, we considered all

11 household members irrespective of baseline serology as susceptible contacts in the HCIR analysis.

12 *Ethics*

13 The study protocol was approved by University of the Witwatersrand Human Research Ethics Committee 14 (Reference M2008114). Participants in follow-up received grocery store vouchers of USD 3 per visit to 15 compensate for time required for specimen collection and interview.

16 **Results**

17 Screening, enrolment and follow-up

From 2 October 2020 to 30 September 2021, we screened 1,531 clinic attendees for SARS-CoV-2;18%
(277) tested positive on rRT-PCR. Of those testing positive who met eligibility criteria for household
enrolment (n=277), 143 (52%) households were approached and 131 (92%) were enrolled. Reasons for
non-inclusion shown in Figure 1. The final cohort consisted of 131 index cases and 457 household
contacts (Figure 1), median household size of 4.

- 1 Twenty-one percent (28/131) of index cases were LWH, and two index cases initially agreed but then
- 2 refused HIV testing after enrolment (classified as HIV unknown during analyses). The majority (93/131,
- 3 71%) of index cases and contacts (265/457, 58%) were female (Table 2).
- 4 Of 10,584 potential study visits to individual participants, we completed 8,509 (80%) visits, and detected
- 5 SARS-CoV-2 in 17% (1,454/8,352) of nasal swabs collected (Supplementary Figure 1).
- 6 Secondary SARS-CoV-2 cases
- 7 We diagnosed 232 (51%) rRT-PCR-confirmed secondary cases from 457 contacts linked to 131 index
- 8 cases. One third (69/232) of secondary cases reported ≥ 1 symptom during their SARS-CoV-2 episode,
- 9 reporting on average 3 symptoms (range 1-9). The mean symptom duration was 11 days (range 4-40). The
- 10 most common symptoms reported were cough (45/69, 65%), headache (31/67, 46%) and fever (27/69, 65%)
- 11 39%). Five secondary cases were hospitalized (Supplementary Table 5).
- 12 Household cumulative infection risk
- Of 131 households, we excluded seven (5%) households from HCIR analysis: four (13 contacts) had SARS-CoV-2 clusters with >1 variant detected (Supplementary Figure 2), and in three (8 contacts) all contacts were seropositive at baseline with no rRT-PCR-confirmed SARS-CoV-2 infection during followup. An additional 42 contacts were excluded because they had prevalent SARS-CoV-2 antibodies at baseline, and no SARS-CoV-2 detection during follow-up. We therefore included 124/131 (95%) index cases with 373/436 (86%) contacts for this analysis.
- The HCIR was 59% (220/373) overall. Mean number of household contacts testing positive for SARSCoV-2 following index episode was 2 (range 0 to 7). On univariate analysis, HCIR was similar in
 households with HIV-uninfected index cases (58%, 173/293) and households where index was LWH
 (60%, 50/83, OR 1.0, 95% CI 0.4-2.3).

1 On multivariable analysis, after adjusting for site and immune suppression, factors associated with

- 2 household transmission were index case aged 35-59 years (aOR 3.4 95% CI 1.5-7.8) and \geq 60 years (aOR
- 3 3.1, 95% CI 1.0-10.1) compared to 18-34 years; index cases with a C_t value <25 (aOR 5.3, 95% CI 1.6-

4 17.6) and 25-35 (aOR 7.5, 95% CI 2.2-26.0) compared to $C_t>35$; infection with Delta variant compared to

- 5 Beta (aOR 4.6, 95% CI 1.5-14.4, Figure 4, Supplementary table 1).
- 6 Fourteen percent (17/124) of index cases were LWH, not immune suppressed, while 3% (4/124) were

7 LWH, immune suppressed. Contacts of index cases LWH with immune suppression, had higher HCIR

8 (62%, 8/13) compared to contacts of index cases not immune suppressed (58%, 30/52), but was not

9 statistically significant on multivariable analysis (aOR 2.5, 95%CI 0.4-15.3). Contact age 13-17 years

- 10 (aOR 7.1, 95%CI 1.5-33.9) and 18-34 years (aOR 4.4, 95%CI 1.0-18.4) compared to <5 years and
- 11 contacts not currently smoking (aOR 3.9, 95%CI 1.7-9.0) were associated with higher HCIR.

12 Episode duration

We right-censored 6% of (8/131) index cases who were SARS-CoV-2 positive on their last specimen collected at the end of follow-up (n=5) or at withdrawal (n=3). When including all 131 index cases, mean episode duration for index cases was 20 days (range 3-47, Figure 2). When excluding the eight rightcensored individuals (n=123), mean episode duration for index cases was 19 days (range 3 to 45). Mean episode duration was similar for HIV-uninfected index cases (20 days, range 3-45) compared to index cases LWH (17 days, range 3-45, HR 0.8, 95% CI 0.5-1.2).

19 On multivariable analysis, factors associated with longer episode duration in days, was Soweto site (aHR

- 20 0.5, 95%CI 0.3-0.7), being 35-59 years old (aHR 0.4, 95%CI 0.2-0.6) and ≥ 60 years (aHR 0.2, 95%CI
- 21 0.1-0.5) compared to 18-34 years, $C_t < 25$ (aHR 0.6, 95% CI 0.2-0.9) compared to $C_t > 35$ (Figure 5,
- 22 Supplementary table 2) and being seropositive at end of follow-up (aHR 0.1, 95% CI 0.0-0.3). Individuals
- 23 infected with Delta variant (aHR 2.6, 95% CI 1.4-5.0) and a non-variant of concern (aHR 4.0, 95% CI 1.9-
- 8.2), compared to Beta, had shorter episode durations (Figure 5, Supplementary Table 2).

Eighty-eight (67%) of index cases had ≥1 specimen with ≥1 target with Ct<30. Mean episode duration
 with Ct<30 was 7 days (range 2-17). On multivariable analysis, factors associated with longer episode
 duration considering only specimens with at least one target with a Ct<30, was female sex (aHR 0.5,
 95% CI 0.3-0.9), LWH (aHR 0.4, 95% CI 0.1-0.9) and being seropositive at the end of follow-up (aHR
 0.01, 95% CI 0.001-0.2, (Figure 5, Supplementary Table 3).

6 Serial interval

We excluded 5 index contact pairs where serial interval was >21 days; three with an HIV-uninfected
index and two pairs where the index was LWH. Mean serial interval for index cases and symptomatic
contact pairs included in the risk factor analysis was 6 days (range 1-20, Figure 3). Mean serial interval
for HIV-uninfected index cases was 6 days (range 1-15) and for index cases LWH 8 days (range 2-20).
On multivariable analysis, pairs with contacts aged 35-59 years (aHR 0.3, 95%CI 0.1-0.9) and ≥60 years
(aHR 0.2, 95%CI 0.0-0.8), compared to being aged 18-34 years, and where the contact was LWH (aHR
0.1, 95%CI 0.0-0.8) had longer serial intervals (Figure 6, Supplementary Table 4).

14 Sensitivity analysis

When not excluding individuals seropositive at baseline with no rRT-PCR-confirmed SARS-CoV-2
infection during follow-up, HCIR was 51% (220/436) overall. We found similar factors associated with
HCIR (Supplementary Table 2). When only including households where 65% of members completed
65% of visits, we included 112 index cases with 342 contacts. Factors associated with HCIR, episode
duration and serial interval were similar to what we observed in the main analysis (Supplementary Tables
6-9)

21 Discussion

We performed a case-ascertained, prospective household transmission study for SARS-CoV-2 in South
Africa, including 131 index cases, 28 of whom were LWH; and 457 household contacts. We observed a

1 59% HCIR, HCIR being higher in households with older index cases and contacts aged 13-17 years and 2 18-34 years. HCIR was also higher in households with Delta-infected index cases vs Beta. The HCIR was 3 similar in index cases LWH and HIV-uninfected index cases. Index episode durations were longer in 4 older aged individuals. Episode duration at high viral load (C_t <30) was longer in index cases LWH and 5 serial interval was longer in contacts LWH.

HCIR from previous studies have varied based on study design, symptom status of index, timing within 6 7 the epidemic[20] and SARS-CoV-2 variant.[16] In our study only including symptomatic index cases, we 8 estimated the HCIR at 59%, a higher estimate than the overall 37% reported from a recent meta-analysis which included 33 studies performed in 2021 and 2022, and the variant-specific 23% and 30% estimates 9 for Beta and Delta variants, respectively.[16] In a Madagascar study including both symptomatic and non-10 symptomatic index cases, HCIR was 39%.[21] The higher estimate seen in our study may be influenced 11 by symptom severity, as proposed in previous studies, [22] or the inclusion of only adult index cases; adult 12 index cases result in higher HCIR.[23] In our study, households with index cases older than 35 years were 13 three times more likely to result in higher HCIR compared to when index cases were aged 18-34 years. 14 HCIR was also higher when contacts were aged 13-17 and 18-34, compared to <5 years. Contacts aged 15 13-18 years were also associated with higher HCIR in the South African PHIRST-C study, [2] although 16 17 studies from earlier in the pandemic showed higher attack rates in elderly household members. [22, 24] 18 This may be related to the shift in age-distribution of cases from the older population to younger individuals with progression of the pandemic. [2, 25, 26] As seen previously, [2, 27, 28] we also observed 19 higher secondary attack rates where the minimum rRT-PCR C_t was lower for the index case, which could 20 21 be considered a proxy for higher viral load.

22 We observed no difference in HCIR in households with index cases living with and without HIV.

23 However, we observed a higher HCIR in people living with HIV (PLWH) who were immune suppressed,

but this association was not statistically significant possibly due to low numbers (n=14) of included

25 immunosuppressed index cases LWH. This would fit with previous studies finding that

immunocompromised PLWH that shed virus at low C_t value for longer[2, 15] allowing longer opportunity
for secondary infections, although we did not observe increases transmission in our study, possibly due to
small numbers.

4 The mean episode duration in index cases of 19 days, was higher than the 11 days reported from the 5 household cohort study from South Africa[2] but more similar to the 18 days estimate from a meta-6 analysis for viral shedding time. [29] This may be due to our analysis being limited to symptomatic 7 individuals, shown to be associated with longer episode duration. [2, 29] Episode duration in this study is 8 also higher than studies on hospitalised South African patients where median episode duration was 13 days[15]. Previous studies from South Africa in the community and in hospitals found that 9 immunocompromised people LWH shed SARS-CoV-2 for longer.[2, 15] While we did not find overall 10 longer shedding in people LWH, when considering detection at $C_1 < 30$ (proxy for high viral load), we also 11 observed people LWH had longer episode durations. Longer episode durations may allow increased 12 opportunity for viral evolution, and the establishment of novel variants [30]. 13

14

Previous serial interval estimates ranged between 4 to 7.5 days[2, 22], similar to our estimate of 6 days.
We did not find any index characteristics related to longer serial intervals, but longer serial intervals were
observed in contacts older than 35 years, and those LWH. Individuals with compromised immune
systems (PLWH, elderly) may still be able to be infected with SARS-CoV-2 towards the end of the index
episode when viral loads are lower. Due to their increased risk for hospitalization and death [9, 13], there
should be continued support for prioritising COVID-19 vaccination in these populations.

21

Our study had limitations. We assumed the first household member presenting with symptoms was the
index case. If the true index cases were asymptomatic, we would have underestimated the serial interval,
although HCIR estimates should not be greatly affected. Due to the delay between index screening and

1 household enrolment, we did not have the exact date of first SARS-CoV-2 positivity in household 2 contacts, and may have also over-estimated HCIR if there were multiple introductions of SARS-CoV-2 in 3 the household. By excluding individuals seropositive at baseline with no SARS-CoV-2 infection during 4 follow-up, we assumed 100% protection from previous infections, which is likely not correct, and may 5 have overestimated HCIR. When including these individuals, HCIR reduced by 8%. We were unable to 6 reach the planned sample size for contacts of index cases LWH, and may have been underpowered to 7 detect some differences. By only including symptomatic index cases, our results may not be generalizable to households with asymptomatic infections. We did not consider the role of age-related contact patterns 8 9 within the household on household transmission. This should be considered for future studies.

In conclusion, in two communities in South Africa, HCIR was higher than in previous studies[16] and not 10 influenced by HIV status. Episode duration at high viral loads (inferred by $C_1 < 30$) was increased for index 11 cases LWH, which may lead to increased risk for secondary transmission and viral evolution. Serial 12 interval was longer in contacts LWH. Although these findings indicate that HIV status of the index case 13 did not affect SARS-CoV-2 transmission to household contacts, it may still play a role, especially if 14 PLWH are not virally suppressed. Sustaining and strengthening HIV treatment and care programs should 15 be a focus moving forward to ensure PLWH are diagnosed and virally suppressed to reduce prolonged 16 17 shedding of SARS-CoV-2 and potentially reduce increased transmission, as well as their risk for hospitalisation and death [9]. 18

- 19
- 20 NOTES
- 21 Author contributions
- 22 Conception and design of study: JK, SW, NAM, AvG, JNB, MW, LL, ST, CC
- 23 Data collection and laboratory processing: AvG, JNB, DGA, AB, KN, NW, LG, LN, JC, LdG, RK
- 24 Analysis and interpretation: JK, SW, ST, CC

- 1 Accessed and verified underlying data: JK, MN, LG, LM, JC
- 2 Drafted the Article: JK
- 3 All authors critically reviewed the Article. All authors had access to all the data reported in the study.

4 Acknowledgements

- 5 All individuals participating in the study, field teams for their hard work and dedication to the study, the
- 6 CRDM laboratory team, Andrew Whitelaw, June Fabian, Themba Radebe and Thoko Sifunda from the
- 7 safety committee.
- 8 This study protocol was adapted from the World Health Organization Unity Studies Early Investigation
- 9 Protocol for Household transmission investigation protocol for COVID-19 infection.

10 Data availability

- 11 The investigators welcome enquiries about possible collaborations and requests for access to the dataset.
- 12 Data will be shared after approval of a proposal and with a signed data access agreement. Investigators
- 13 interested in more details about this study, or in accessing these resources, should contact the

14 corresponding author.

15 Funding

This research was funded by the Wellcome Trust (Grant number 221003/Z/20/Z) in collaboration with the 16 17 Foreign, Commonwealth and Development Office, United Kingdom. For the purpose of open access, the 18 author has applied a CC BY-ND public copyright licence to any Author Accepted Manuscript version 19 arising from this submission. AvG, JK, and SW also report grants paid to institution in support of this 20 work from WHO AFRO, Africa Pathogen Genomics Initiative (Africa PGI) through African Society of Laboratory Medicine (ASLM) and Africa CDC, US Centers for Disease Control and Prevention, South 21 African Medical Research Council (SAMRC), and UK Department of Health and Social Care and 22 23 managed by the Fleming Fund: SEQAFRICA project. LL and NW also report support for this work from

the US Centre for Disease Control and Prevention. MN reports support for this work paid to institution
 from America Centre for Disease Control. NAM reports support for this work paid to institution from the
 National Institute of Communicable Diseases.

4 Potential conflicts of interest

5 CC has received grant support from Sanofi Pasteur, US Centers for Disease Control and Prevention,

6 Welcome Trust, Programme for Applied Technologies in Health (PATH), Bill & Melinda Gates

7 Foundation and South African Medical Research Council (SA-MRC). NW, AvG , JK, and SW report

8 receiving grant funds paid to institution from Sanofi Pasteur and Bill & Melinda Gates Foundation. AvG

9 also reports an unpaid position as Chairperson of National Advisory Group on Immunisation. LL reports

10 receiving grant funds from US Centers for Disease Control and Prevention, and Bill & Melinda Gates

11 Foundation. NM reports receiving grant funds paid to institution from Pfizer to conduct observational

12 studies into the burden of pneumonia in South Africa; unpaid participation on a data safety monitoring

13 board of a TB HDT trial and Scientific Advisory Board on a trial of a electronic reminder to take daily TB

14 treatment; and unpaid leadership or fiduciary role with Setshaba Research Center. SW also reports an

15 unpaid leadership or fiduciary role in other board, society, committee or advocacy group. All other

16 authors have no competing/conflict of interest.

References

2	1.	Africa CDC. Africa CDC COVID-19 Dashboard. Available at: <u>https://africacdc.org/covid-</u>
3		<u>19/</u> . Accessed 25 January.
4	2.	Cohen C, Kleynhans J, von Gottberg A, et al. SARS-CoV-2 incidence, transmission, and
5		reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South
6		Africa, 2020-21. The Lancet Infectious Diseases 2022.
7	3.	Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-
8		CoV-2 omicron variant in South Africa: a data linkage study. The Lancet 2022; 339(10323):
9		437-46.
10	4.	UNAIDS. UNAIDS Data 2020, 2020.
11	5.	Dorward J, Khubone T, Gate K, et al. The impact of the COVID-19 lockdown on HIV care in
12		65 South African primary care clinics: an interrupted time series analysis. The Lancet HIV
13		2021 ; 8(3): e158-e65.
14	6.	Harris TG, Jaszi E, Lamb MR, et al. Effects of the COVID-19 Pandemic on HIV Services:
15		Findings from 11 Sub-Saharan African Countries. Clin Infect Dis 2021.
16	7.	Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration
17		and pseudovirus neutralising antibody titres after infection, compared by HIV status: a
18		matched case-control observational study. Lancet HIV 2021: S2352-3018(21)00072-2.
19	8.	Ambrosioni J, Blanco JL, Reyes-Urueña JM, et al. Overview of SARS-CoV-2 infection in
20		adults living with HIV. Lancet HIV 2021; 8(5): e294-e305.
21	9.	Tesoriero JM, Swain C-AE, Pierce JL, et al. COVID-19 Outcomes Among Persons Living
22		With or Without Diagnosed HIV Infection in New York State. JAMA Network Open 2021;
23		4(2): e2037069-е.
24	10.	Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-
25		19 co-infection: a systematic review and meta-analysis. AIDS Res Ther 2022; 19(1): 3.

1	11.	Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19
2		in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep 2021; 11(1):
3		6283
4	12.	Dong Y, Li Z, Ding S, et al. HIV infection and risk of COVID-19 mortality: A meta-analysis.
5		Medicine 2021 ; 100(26): e26573.
6	13.	Jassat W, Cohen C, Tempia S, et al. Risk factors for COVID-19-related in-hospital mortality
7		in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. The Lancet
8		HIV 2021 ; 8(9): e554-e67.
9	14.	Friedman EE, Devlin SA, McNulty MC, Ridgway JP. SARS-CoV-2 percent positivity and
10		risk factors among people with HIV at an urban academic medical center. PLoS One 2021;
11		16(7): e0254994.
12	15.	Meiring S, Tempia S, Bhiman JN, et al. Prolonged shedding of SARS-CoV-2 at high viral
13		loads amongst hospitalised immunocompromised persons living with HIV, South Africa. Clin
14		Infect Dis 2022.
15	16.	Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Secondary Attack
16		Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review
17		and Meta-analysis. JAMA Network Open 2022; 5(4): e229317-e.
18	17.	Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
19		community of software platform partners. J Biomed Inform 2019; 95: 103208-18.
20	18.	Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by
21		South African COVID-19 donor plasma. Nat Med 2021; 27(4): 622-5.
22	19.	Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with
23		RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro
24	Y	Surveill 2020 ; 25(32): 2001483.
25	20.	Hsu C-Y, Wang J-T, Huang K-C, Fan AC-H, Yeh Y-P, Chen SL-S. Household transmission
26		but without the community-acquired outbreak of COVID-19 in Taiwan. J Formos Med Assoc
27		2021 ; 120: S38-S45.

1	21.	Ratovoson R, Razafimahatratra R, Randriamanantsoa L, et al. Household transmission of
2		COVID-19 among the earliest cases in Antananarivo, Madagascar. Influenza Other Respir
3		Viruses 2022 ; 16(1): 48-55.
4	22.	Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
5		Coronavirus-Infected Pneumonia. The New England journal of medicine 2020:
6		10.1056/NEJMoa2001316.
7	23.	Koh WC, Naing L, Chaw L, et al. What do we know about SARS-CoV-2 transmission? A
8		systematic review and meta-analysis of the secondary attack rate and associated risk factors.
9		PLoS One 2020 ; 15(10): e0240205.
10	24.	Jing Q-L, Liu M-J, Zhang Z-B, et al. Household secondary attack rate of COVID-19 and
11		associated determinants in Guangzhou, China: a retrospective cohort study. The Lancet
12		Infectious Diseases 2020 ; 20(10): 1141-50.
13	25.	Malmgren J, Guo B, Kaplan HG. Continued proportional age shift of confirmed positive
14		COVID-19 incidence over time to children and young adults: Washington State March-
15		August 2020. PLoS One 2021 ; 16(3): e0243042.
16	26.	Kleynhans J, Tempia S, Wolter N, et al. SARS-CoV-2 Seroprevalence in a Rural and Urban
17		Household Cohort during First and Second Waves of Infections, South Africa, July 2020-
18		March 2021. Emerging Infectious Disease journal 2021; 27(12): 3020.
19	27.	Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in
20		Catalonia, Spain: a cohort study. The Lancet Infectious Diseases 2021; 21(5): 629-36.
21	28.	Cerami C, Popkin-Hall ZR, Rapp T, et al. Household transmission of SARS-CoV-2 in the
22	C	United States: living density, viral load, and disproportionate impact on communities of color.
23		Clin Infect Dis 2021.
24	29.	Yan D, Zhang X, Chen C, et al. Characteristics of Viral Shedding Time in SARS-CoV-2
25	P	Infections: A Systematic Review and Meta-Analysis. Frontiers in Public Health 2021; 9(209).
26	30.	Van Egeren D, Novokhodko A, Stoddard M, et al. Controlling long-term SARS-CoV-2
27		infections can slow viral evolution and reduce the risk of treatment failure. Sci Rep 2021;
28		11(1): 22630.

1	31.	Sun K, Tempia S, Kleynhans J, et al. Persistence of SARS-CoV-2 immunity, Omicron's
2		footprints, and projections of epidemic resurgences in South African population cohorts.
3		medRxiv 2022 : 2022.02.11.22270854.
4	32.	Ong SWX, Chiew CJ, Ang LW, et al. Clinical and Virological Features of Severe Acute
5		Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective
6		Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect
7		Dis 2021.
8	33.	Shastri MD, Shukla SD, Chong WC, et al. Smoking and COVID-19: What we know so far.
9		Respir Med 2021 ; 176: 106237
10	34.	Vallarta-Robledo JR, Sandoval JL, Baggio S, et al. Negative Association Between Smoking
11		and Positive SARS-CoV-2 Testing: Results From a Swiss Outpatient Sample Population.
12		Frontiers in Public Health 2021; 9.
13		CERTER MAN

1 Tables

Table 1. Definitions

Household	A group of three or more people who regularly share at least two meals in the same
	residence at least two days per week (residential institutions excluded).
Index case	The first household member who had COVID-like-symptoms. We assumed that
	the household member screened was the index case within the household as they
	were the first household member to develop symptoms
SARS-CoV-2 infection	At least one nasal swab rRT-PCR positive for SARS-CoV-2. Individuals who
episode	seroconverted during follow-up but with no rRT-PCR-confirmed infection were
	not included in secondary case analyses.
SARS-CoV-2 cluster	Composed of all infections within a household within an interval between
	infections of ≤ 2 weeks including single infections within a household.
Episode duration	Duration of SARS-CoV-2 positivity. The start of symptom onset to the midpoint
	between the last positive swab and first negative. Individuals who were still SARS-
	CoV-2 positive on the last study visit (whether at end of follow-up or due to early
	withdrawal) were right-censored for the multivariable analysis.
Serial interval	Number of days between the onset of symptoms in the index case, to the onset of
	symptoms in the secondary case. The serial interval was the. Multivariable
	analyses were restricted to symptomatic secondary cases, and restricted to serial
	interval periods of ≤ 21 days as longer serial intervals could have been due to
	tertiary cases or secondary infections.
Household cumulative	The percentage of susceptible household members (based on baseline serology)
infection risk (HCIR)	that had at least one SARS-CoV-2 positive swab from the start of follow-up, up to
	two weeks from the last SARS-CoV-2 positive swab of the index case.
	Considering susceptibility was important because following the second wave of
	SARS-CoV-2 infection in South Africa, 41% of individuals were estimated to have
	had previous SARS-CoV-2 infection. ^[26] Individuals with SARS-CoV-2 antibodies
	detected at baseline, but also tested positive on rRT-PCR, were included in the
	HCIR calculation. Individuals for whom no baseline serology was available were
	included in the analysis as presumed susceptible. We did not consider any
	secondary introductions in the household for our analysis. Households where
	members had SARS-CoV-2 infection with different variants of concern were
	excluded from the analysis.

- 1 Table 2. Baseline characteristics of SARS-CoV-2 index cases (n=131) and their household contacts (n=457), Klerksdorp and Soweto, South Africa,
- 2 September 2020 October 2021.

	Over	all	Index Cas	e, n/N (%)	Household con	ontact, n/N (%)	
Characteristic	Index Case, n/N (%)	Household contact, n/N (%)	Klerksdorp	Soweto	Klerksdorp	Soweto	
Household Characteristics							
Index case/contact	131/588 (22)	457/588 (78)	62/274 (23)	69/314 (22)	212/274 (77)	245/314 (78)	
Household size							
3-5	106/131 (81)	305/457 (67)	51/62 (82)	55/69 (80)	146/212 (69)	159/245 (65)	
6-10	25/131 (19)	152/457 (33)	11/62 (18)	14/69 (20)	66/212 (31)	86/245 (35)	
Rooms used for sleeping							
1-2	66/117 (56)	209/401 (52)	33/57 (58)	33/60 (55)	114/192 (59)	95/209 (45)	
3-4	42/117 (36)	141/401 (35)	22/57 (39)	20/60 (33)	69/192 (36)	72/209 (34)	
>4	9/117 (8)	51/401 (13)	2/57 (4)	7/60 (12)	9/192 (5)	42/209 (20)	
Crowding	89/131 (68)	330/457 (72)	43/62 (69)	46/69 (67)	158/212 (75)	172/245 (70)	
Child <5 years	17/131 (13)	63/457 (14)	10/62 (16)	7/69 (10)	43/212 (20)	20/245 (8)	
HH member smokes inside	30/131 (23)	93/457 (20)	18/62 (29)	12/69 (17)	51/212 (24)	42/245 (17)	
Main water source inside home	92/131 (70)	321/457 (70)	38/62 (61)	54/69 (78)	124/212 (58)	197/245 (80)	
Place to wash hands inside	129/131 (98)	451/457 (99)	62/62 (100)	67/69 (97)	212/212 (100)	239/245 (98)	

		ć	2							
Overall Index Case, n/N (%) Household contact, n/N (%)										
Characteristic	Index Case, n/N (%)	Household contact, n/N (%)	Klerksdorp	Soweto	Klerksdorp	Soweto				
Main cooking fuel		×								
Electricity	127/131 (97)	444/457 (97)	58/62 (94)	69/69 (100)	199/212 (94)	245/245 (100)				
Gas/Paraffin	4/131 (3)	13/457 (3)	4/62 (6)	0/69 (0)	13/212 (6)	0/245 (0)				
Monthly household income	Y									
<r400< td=""><td>5/131 (4)</td><td>17/457 (4)</td><td>4/62 (6)</td><td>1/69 (1)</td><td>15/212 (7)</td><td>2/245 (1)</td></r400<>	5/131 (4)	17/457 (4)	4/62 (6)	1/69 (1)	15/212 (7)	2/245 (1)				
R401 to R800	6/131 (5)	19/457 (4)	4/62 (6)	2/69 (3)	12/212 (6)	7/245 (3)				
R801 to R1 600	12/131 (9)	39/457 (9)	10/62 (16)	2/69 (3)	33/212 (16)	6/245 (2)				
R1 601 to R3 200	23/131 (18)	86/457 (19)	12/62 (19)	11/69 (16)	43/212 (20)	43/245 (18)				
R3 201 to R6 400	21/131 (16)	68/457 (15)	7/62 (11)	14/69 (20)	23/212 (11)	45/245 (18)				
R6 401 to R12 800	8/131 (6)	33/457 (7)	2/62 (3)	6/69 (9)	5/212 (2)	28/245 (11)				
R12 801 to R25 600	6/131 (5)	19/457 (4)	0/62 (0)	6/69 (9)	0/212 (0)	19/245 (8)				
Refused to disclose	50/131 (38)	176/457 (39)	23/62 (37)	27/69 (39)	81/212 (38)	95/245 (39)				
Individual characteristics										
Age										
<5		19/457 (4)			11/212 (5)	8/245 (3)				
5-12		80/457 (18)			39/212 (18)	41/245 (17)				

		ć	3			
	Over	rall	Index Case	e, n/N (%)	Household con	ntact, n/N (%)
Characteristic	Index Case, n/N (%)	Household contact, n/N (%)	Klerksdorp	Soweto	Klerksdorp	Soweto
13-17		70/457 (15)			38/212 (18)	32/245 (13)
18-34	37/131 (28)	126/457 (28)	21/62 (34)	16/69 (23)	54/212 (25)	72/245 (29)
35-59	76/131 (58)	113/457 (25)	37/62 (60)	39/69 (57)	50/212 (24)	63/245 (26)
≥60	18/131 (14)	49/457 (11)	4/62 (6)	14/69 (20)	20/212 (9)	29/245 (12)
Sex						
Male	38/131 (29)	192/457 (42)	17/62 (27)	21/69 (30)	93/212 (44)	99/245 (40)
Female	93/131 (71)	265/457 (58)	45/62 (73)	48/69 (70)	119/212 (56)	146/245 (60)
Level of education*						
No schooling	6/129 (5)	15/283 (5)	3/60 (5)	3/69 (4)	1/120 (1)	14/163 (9)
Primary	4/129 (3)	21/283 (7)	2/60 (3)	2/69 (3)	14/120 (12)	7/163 (4)
Secondary	43/129 (33)	89/283 (31)	25/60 (42)	18/69 (26)	47/120 (39)	42/163 (26)
Matriculation	69/129 (53)	136/283 (48)	28/60 (47)	41/69 (59)	51/120 (43)	85/163 (52)
Post-secondary	7/129 (5)	22/283 (8)	2/60 (3)	5/69 (7)	7/120 (6)	15/163 (9)
Employment*						
Unemployed	55/121 (45)	159/258 (62)	25/57 (44)	30/64 (47)	68/111 (61)	91/147 (62)
Student	10/121 (8)	30/258 (12)	5/57 (9)	5/64 (8)	11/111 (10)	19/147 (13)

			2							
Overall Index Case, n/N (%) Household contact, n/N (%)										
Characteristic	Index Case, n/N (%)	Household contact, n/N (%)	Klerksdorp	Soweto	Klerksdorp	Soweto				
Employed	56/121 (46)	69/258 (27)	27/57 (47)	29/64 (45)	32/111 (29)	37/147 (25)				
Smoking cigarettes†	17/129 (13)	66/323 (20)	11/60 (18)	6/69 (9)	35/145 (24)	31/178 (17)				
Smoke indoors	5/17 (29)	15/66 (23)	5/11 (45)	0/6 (0)	14/35 (40)	1/31 (3)				
HIV status	Y									
HIV-uninfected	101/131 (77)	176/457 (39)	51/62 (82)	50/69 (72)	130/212 (61)	46/245 (19)				
HIV-infected	28/131 (21)	35/457 (8)	10/62 (16)	18/69 (26)	16/212 (8)	19/245 (8)				
HIV status unknown	2/131 (2)	246/457 (54)	1/62 (2)	1/69 (1)	66/212 (31)	180/245 (73)				
HIV infected index in household										
Index HIV negative	101/131 (77)	344/457 (75)	51/62 (82)	50/69 (72)	175/212 (83)	169/245 (69)				
Index HIV positive	28/131 (21)	103/457 (23)	10/62 (16)	18/69 (26)	34/212 (16)	69/245 (28)				
Index HIV unknown	2/131 (2)	10/457 (2)	1/62 (2)	1/69 (1)	3/212 (1)	7/245 (3)				
CD4+ T cell count										
HIV-infected, not immune suppressed‡	17/28 (61)	13/35 (37)	5/10 (50)	12/18 (67)	2/16 (13)	11/19 (58)				
HIV-infected, immune suppressed‡	4/28 (14)	2/35 (6)	1/10 (10)	3/18 (17)	1/16 (6)	1/19 (5)				
HIV-infected no CD4+ T cell count	7/28 (25)	20/35 (57)	4/10 (40)	3/18 (17)	13/16 (81)	7/19 (37)				
Underlying illness§	32/129 (25)	57/448 (13)	12/60 (20)	20/69 (29)	205/212 (97)	243/245 (99)				

		ć	3			
	Ove	rall	Index Case	e, n/N (%)	Household con	ntact, n/N (%)
Characteristic	Index Case, n/N (%)	Household contact, n/N (%)	Klerksdorp	Soweto	Klerksdorp	Soweto
Body-mass index		Y				
Underweight	3/129 (2)	29/448 (6)	1/60 (2)	2/69 (3)	14/205 (7)	15/243 (6)
Normal	36/129 (28)	206/448 (46)	18/60 (30)	18/69 (26)	108/205 (53)	98/243 (40)
Overweight	25/129 (19)	103/448 (23)	10/60 (17)	15/69 (22)	39/205 (19)	64/243 (26)
Obese	65/129 (50)	110/448 (25)	31/60 (52)	34/69 (49)	44/205 (21)	66/243 (27)
Previous TB	7/129 (5)	9/448 (2)	2/60 (3)	5/69 (7)	6/205 (3)	3/243 (1)
Current TB	4/129 (3)	2/448 (0)	2/60 (3)	2/69 (3)	0/205 (0)	2/243 (1)
COVID-19 vaccination¶	0/131 (0)	1/457 (0)	0/62 (0)	0/69 (0)	1/212 (0)	0/245 (0)

1 *Individuals ≥18 years old. †Individuals ≥15 years old. ‡Immune suppressed defined as CD4+ T cell count <200 cells/ml §Underlying medical conditions: Self-reported

2 history of diabetes, hypertension, asthma, lung disease, heart disease, stroke, spinal cord injury, epilepsy, cancer, liver disease, renal disease, pre-maturity. ¶At least one dose

3 administered 14 days prior to enrolment.

1 **Figures**

- 2 Figure 1. Adult SARS-CoV-2 index cases and household contacts enrolled, Klerksdorp and Soweto, 3 South Africa, 2020-2021.
- Figure 2. SARS-CoV-2 episode duration in HIV-infected and HIV-uninfected index cases, 4

5 Klerksdorp and Soweto, South Africa, 2020-2021, (n=123). Excludes those positive at last specimen 6 collected.

7 Figure 3. Interval between onset of symptoms in the index case and onset of symptoms in household

8 contacts with SARS-CoV-2 (serial interval) by HIV-infection status of the index case, Klerksdorp and

9 Soweto, South Africa, 2020-2021, (n=69). Arrow indicates cut-off for inclusion in analysis for factors

- 10 associated with serial interval duration
- Figure 4. Factors associated with SARS-CoV-2 household transmission in index cases and 11

acquisition in household contacts on multivariable logistic regression, Klerksdorp and Soweto, South 12


13 Africa, 2020-2021, (n=373).


Figure 5. Factors associated with SARS-CoV-2 episode duration (irrespective of C_t value left, C_t<30 14

- right) in index cases on Weibull accelerated failure time regression, Klerksdorp and Soweto, South 15
- Africa, 2020-2021, (n=123). 16

Figure 6. Factors associated with serial interval of SARS-CoV-2 in cases with symptomatic illness on 17

- 18 Weibull accelerated failure time regression, Klerksdorp and Soweto, South Africa, 2020-2021,
- 19 (n=62).
- 20
- 21










Figure 6 140x102 mm (0.9 x DPI)